Ganga Pharmaceuticals Limited has scheduled its 37th Annual General Meeting (AGM) for Saturday, September 26, 2026. The meeting will convene at 4:30 pm at the company’s registered office in Virar East, Palghar.

The Board of Directors notified BSE Limited on September 1, 2026, regarding the convening of the AGM and the release of the Integrated Annual Report for FY26. The notice was signed by Bharat Sharma, Managing Director. In compliance with Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company issued letters to shareholders without registered email addresses, providing web links to access the AGM notice and annual report on the company website and the BSE exchange portal.

Key Agenda Items

The AGM will transact both ordinary and special business. Shareholders will consider the adoption of the audited financial statements for the year ended March 31, 2026. Additionally, Mr. Sanjay Kulkarni (DIN: 00065190), Non-Executive Chairman, retires by rotation and offers himself for re-appointment.

A special resolution seeks shareholder approval for the re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director & CEO for a three-year term from April 1, 2026, to March 31, 2029. His remuneration is capped at ₹21.6 lakh per annum.

Financial Performance FY26

The explanatory statement accompanying the notice discloses key financial metrics for FY26 compared to FY25. Total income rose slightly to ₹310.70 crore from ₹307.33 crore. Profit after tax expanded to ₹10.15 crore from ₹7.90 crore.

Voting and Book Closure Details

Shareholders must adhere to specific dates to exercise their voting rights. The cut-off date for determining eligibility to vote is Friday, September 18, 2026.

The company will utilize the remote e-voting system of Central Depository Services Limited (CDSL). The e-voting window opens on Wednesday, September 23, 2026, at 9:00 am and closes on Friday, September 25, 2026, at 5:00 pm.

Shareholders are urged to register their email IDs with their Depository Participants or the company’s RTA to receive future financial reports and corporate benefits electronically.

Regulatory Compliance

Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and Share Transfer Books will remain closed from Sunday, September 20, 2026, through Saturday, September 26, 2026. This closure applies to equity shares for the purpose of the AGM.

The Annual Report and AGM Notice are available on the company website, www.ayurvedganga.com , in compliance with Regulation 34(1) of the SEBI LODR Regulations, 2015.

Ganga Pharmaceuticals Limited has appointed M/s. D Maurya & Associates as its Secretarial Auditor for the financial year 2026-27. The decision was approved by the company's Board of Directors during a meeting held on May 21, 2026, based on the recommendation of the Audit Committee.

The appointment was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The firm, led by Mr. Dhirendra Maurya, a Practicing Company Secretary, will oversee the secretarial audit compliance for the company.

Details of the Appointment

The Board Meeting, which commenced at 03:30 p.m. and concluded at 4:00 p.m., sanctioned the appointment. The tenure for the auditor covers the financial year 2026-27. The disclosure regarding this change has been made in accordance with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Profile of the Auditor

M/s. D Maurya & Associates is a Mumbai-based proprietary firm established in 2010. Mr. Dhirendra Maurya, the proprietor, is an Associate Member of the Institute of Company Secretaries of India (ICSI) with Membership No. 22005. He holds a Certificate of Practice No. 9594 and a Peer Review Certificate 2544/2022.

The company confirmed that there are no relationships to disclose between the directors of Ganga Pharmaceuticals Limited and the newly appointed auditor. The information is available on the company's website.